Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Demographic characteristics, clinical, and laboratory data of patients at time of blood sampling at initial evaluation

From: Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis

  DM (n = 22) PM (n = 41) All (n = 63)
Female:male 15:7 28:13 43:20
Age (years), mean ± SD 52.5 ± 10.9 52 ± 12.6 52.2 ± 11.9
Years of symptoms 5.9 (0.1–31.0) 3.8 (0.2–23.8) 4.1 (0.1–31.0)
Years from diagnosis 1.3 (0–29.0) 0.8 (0–23.3) 1.0 (0–29.0)
Early casesa, n (%) 10 (45%) 20 (49%) 30 (48%)
ILD, n (%) 15 (68%) 33 (80.5%) 48 (76%)
Medication, n (%)
 GC 20 (91%) 36 (88%) 56 (89%)
 DMARDs 11 (50%) 23 (56%) 34 (54%)
 No therapy 1 (4.5%) 4 (10%) 5 (8%)
Dose of GC (mg/day)b 15 (0–80) 17.5 (0–85) 17.5 (0–85)
MDAAT visual analogue scale (mm) (n = 20) (n = 38) (n = 58)
 Constitutional 1 (0–35) 0 (0–25) 0 (0–35)
 Cutaneous 10 (0–30) 0 (0–21) 1 (0–30)
 Skeletal 0 (0–43) 0 (0–63) 0 (0–63)
 Gastrointestinal 0 (0–17) 0 (0–27) 0 (0–27)
 Pulmonary 11 (0–86) 13 (0–66) 12.5 (0–86)
 Cardiac 0 (0–10) 0 (0–36) 0 (0–36)
 Other 0 (0–17) 0 (0–29) 0 (0–29)
 Extramuscular global 11.5 (0–64) 17.5 (0–44) 15 (0–64)
 Muscle 7.5 (0–82) 11.3 (0–71) 11 (0–82)
 Global 21 (0–79) 16.5 (0–59) 17.5 (0–79)
MYOACT scorec 0.07 (0–0.26) 0.05 (0–0.23) 0.06 (0–0.26)
  n   n   n  
BAFF (ng/ml) 22 2.1 (0.8–20.9) 41 1.7 (0.3–18.7) 63 1.8 (0.3–20.9)
anti-Jo-1 (kU/l) 22 127 (0.6–2135) 41 178 (0.8–3605) 63 162 (0.6–3605)
CK (μkat/l) 22 1.8 (0.25–94.5) 41 3.6 (0.3–78.4) 63 2.6 (0.25–94.5)
Myoglobin (μg/l) 19 80 (24 - 5313) 34 115 (10.6–3498) 53 94 (10.6–5313)
ALT (μkat/l) 22 0.4 (0.1–6.7) 40 0.5 (0.1–3.6) 62 0.5 (0.1–6.7)
AST (μkat/l) 21 0.5 (0.1–5.1) 40 0.4 (0.2–6.5) 61 0.4 (0.1–6.5)
CRP (mg/l) 22 3.0 (0.2–29.4) 38 3.5 (0.5–54.8) 60 3.25 (0.2–54.8)
  1. Data are shown as median (range; minimum–maximum) unless otherwise stated
  2. Myoglobin normal levels < 92 μg/l for men and < 76 μg/l for women
  3. ALT alanine aminotransferase (normal levels < 0.75 μkat/l for men and < 0.57 μkat/l for women), AST aspartate aminotransferase (normal levels < 0.58 μkat/L for men and < 0.52 μkat/L for women), BAFF B-cell activating factor of the tumour necrosis factor family, CK creatine kinase (normal levels for Swedish cohort < 2.5 μkat/L for men and < 2.0 μkat/L for women, and for Czech cohort < 2.85 μkat/l and < 2.42 μkat/l), CRP= C-reactive protein (normal levels < 5 mg/l), DM dermatomyositis, DMARD disease-modifying anti-rheumatic drug, GC glucocorticoids, ILD interstitial lung disease (ever present), MDAAT Myositis Disease Activity Assessment Tool, PM polymyositis
  4. aEarly case = disease duration up to 6 months
  5. bEquivalent of prednisone
  6. cMYOACT score is the sum of the 10-cm visual analogue scale scores for each of the six individual organ systems divided by the total maximum possible score